Epidemiologic Reviews 24:80-84 (2002)
© 2002 Johns Hopkins Bloomberg School of Public Health
Economic Endpoints in Clinical Trials
1 The Department of Health Research and Policy and Department of Medicine, Stanford University School of Medicine, HRP Redwood Building, Room 150, Stanford, CA 94305-5405 e-mail:hlatky{at}stanford.edu
November 2, 2001; March 15, 2002
Economic endpoints are increasingly common in randomized clinical trials. As a relatively new addition to the field, methods of measuring and analyzing cost data are still evolving. These developments will be stimulated by the demands of the public for efficient and effective medical care, which will be based on the findings of clinical trials.